» Articles » PMID: 25474037

Expansion of CTCs from Early Stage Lung Cancer Patients Using a Microfluidic Co-culture Model

Abstract

The potential utility of circulating tumor cells (CTCs) to guide clinical care in oncology patients has gained momentum with emerging micro- and nanotechnologies. Establishing the role of CTCs in tumor progression and metastasis depends both on enumeration and on obtaining sufficient numbers of CTCs for downstream assays. The numbers of CTCs are few in early stages of cancer, limiting detailed molecular characterization. Recent attempts in the literature to culture CTCs isolated from metastatic patients using monoculture have had limited success rates of less than 20%. Herein, we have developed a novel in-situ capture and culture methodology for ex-vivo expansion of CTCs using a three dimensional co-culture model, simulating a tumor microenvironment to support tumor development. We have successfully expanded CTCs isolated from 14 of 19 early stage lung cancer patients. Expanded lung CTCs carried mutations of the TP53 gene identical to those observed in the matched primary tumors. Next-generation sequencing further revealed additional matched mutations between primary tumor and CTCs of cancer-related genes. This strategy sets the stage to further characterize the biology of CTCs derived from patients with early lung cancers, thereby leading to a better understanding of these putative drivers of metastasis.

Citing Articles

3D cell culture models in research: applications to lung cancer pharmacology.

Vella N, Fenech A, Petroni Magri V Front Pharmacol. 2024; 15:1438067.

PMID: 39376603 PMC: 11456561. DOI: 10.3389/fphar.2024.1438067.


Unique Cohorts of Salivary Gland Cancer Cells as an Model of Circulating Tumor Cells.

Mincy C, Revelt L, Carter K, Reed D, Joy A J Maxillofac Oral Surg. 2024; 23(4):896-908.

PMID: 39118911 PMC: 11303642. DOI: 10.1007/s12663-024-02250-0.


Spheroids and organoids derived from colorectal cancer as tools for drug screening.

Ahmad Zawawi S, Salleh E, Musa M Explor Target Antitumor Ther. 2024; 5(2):409-431.

PMID: 38745769 PMC: 11090692. DOI: 10.37349/etat.2024.00226.


Applied models and molecular characteristics of small cell lung cancer.

Mihalekne Fur G, Nemes K, Mago E, Beno A, Topolcsanyi P, Moldvay J Pathol Oncol Res. 2024; 30:1611743.

PMID: 38711976 PMC: 11070512. DOI: 10.3389/pore.2024.1611743.


Tumour organoids and assembloids: Patient-derived cancer avatars for immunotherapy.

Mei J, Liu X, Tian H, Chen Y, Cao Y, Zeng J Clin Transl Med. 2024; 14(4):e1656.

PMID: 38664597 PMC: 11045561. DOI: 10.1002/ctm2.1656.


References
1.
Yamaguchi T, Yanagisawa K, Sugiyama R, Hosono Y, Shimada Y, Arima C . NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell. 2012; 21(3):348-61. DOI: 10.1016/j.ccr.2012.02.008. View

2.
Kang J, Krause S, Tobin H, Mammoto A, Kanapathipillai M, Ingber D . A combined micromagnetic-microfluidic device for rapid capture and culture of rare circulating tumor cells. Lab Chip. 2012; 12(12):2175-81. DOI: 10.1039/c2lc40072c. View

3.
Stott S, Lee R, Nagrath S, Yu M, Miyamoto D, Ulkus L . Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med. 2010; 2(25):25ra23. PMC: 3141292. DOI: 10.1126/scitranslmed.3000403. View

4.
Bethune G, Bethune D, Ridgway N, Xu Z . Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J Thorac Dis. 2012; 2(1):48-51. PMC: 3256436. View

5.
Mogi A, Kuwano H . TP53 mutations in nonsmall cell lung cancer. J Biomed Biotechnol. 2011; 2011:583929. PMC: 3035360. DOI: 10.1155/2011/583929. View